Clinical Trials Browser

Phase 1/2 × olverembatinib × 1 year × Clear all

NCT04501120 2025-09-26

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute